An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

被引：0

作者：

Saiag, P. ^{[1
]}

Robert, C. ^{[2
]}

Grob, J. J. ^{[3
,4
]}

Mortier, L. ^{[5
]}

Dereure, O. ^{[6
]}

Lebbe, C. ^{[7
]}

Mansard, S. ^{[8
]}

Grange, F. ^{[9
]}

Neidhardt, E-M. ^{[10
]}

Lesimple, T. ^{[11
]}

Machet, L. ^{[12
,13
]}

Bedane, C. ^{[14
]}

Jeudy, G. ^{[15
]}

Aubin, F. ^{[16
]}

Dreno, B. ^{[17
]}

Szenik, A. ^{[18
]}

Denden, A. ^{[18
]}

Dutriaux, C. ^{[19
]}

机构：

[1] Ambroise Pare Hosp, AP HP, Dept Dermatol, Boulogne, France

[2] Inst Gustave Roussy, Dept Dermatol, Villejuif, France

[3] Aix Marseille Univ, Dept Dermatol, Marseille, France

[4] Univ Hosp Timone, APHM, Marseille, France

[5] Hop Claude Huriez, Dept Dermatol, Lille, France

[6] CHU Montpellier, Dept Dermatol, Montpellier, France

[7] Hop St Louis, Dept Dermatol Oncol, Paris, France

[8] CHU Estaing, Dept Dermatol, Clermont Ferrand, France

[9] Hosp Robert Debre, CHU Reims, Dept Dermatol, Reims, France

[10] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[11] Eugene Marquis Ctr, Dept Med Oncol, Rennes, France

[12] CHRU Tours, Dept Dermatol, Tours, France

[13] Univ Francois Rabelais Tours, Tours, France

[14] Hop Dupuytren, CHU Limoges, Dept Dermatol, Limoges, France

[15] Dijon Univ Hosp, Dept Dermatol, Dijon, France

[16] Besancon Univ Hosp, Dept Dermatol, EA3181, Besancon, France

[17] Ctr Hosp Univ Nantes, Dept Dermatol, Nantes, France

[18] Novartis Pharma France, Dept Med Oncol, Rueil Malmaison, France

[19] Hop St Andre, CHU Bordeaux, Dept Dermatol, Bordeaux, France

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1260P

引用

页数：2